CD52+ regulatory T cells and CD52-expressing sperms downregulated in couples with unexplained infertility: A case-control study

被引：0
|
作者：
Raeisi, Mohammad [1 ]
Kalantar, Kurosh [1 ]
Jahromi, Bahia Namavar [2 ,3 ]
Gharesi-Fard, Behrouz [1 ,3 ]
机构：
[1] Shiraz Univ Med Sci, Dept Immunol, Zand St, Shiraz, Iran
[2] Shiraz Univ Med Sci, Dept Obstet & Gynecol, Shiraz, Iran
[3] Shiraz Univ Med Sci, Infertil Res Ctr, Shiraz, Iran
来源：
INTERNATIONAL JOURNAL OF REPRODUCTIVE BIOMEDICINE | 2020年 / 18卷 / 05期
关键词：
D O I：
10.18502/ijrm.v13i5.7159
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：385 / 387
页数：3
相关论文
共 50 条
  • [1] Immune regulation by CD52-expressing CD4 T cells
    Toh, Ban-Hock
    Kyaw, Tin
    Tipping, Peter
    Bobik, Alex
    CELLULAR & MOLECULAR IMMUNOLOGY, 2013, 10 (05) : 379 - 382
  • [2] Immune regulation by CD52-expressing CD4 T cells
    Ban-Hock Toh
    Tin Kyaw
    Peter Tipping
    Alex Bobik
    Cellular & Molecular Immunology, 2013, 10 : 379 - 382
  • [3] CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells
    Watanabe, Tomoko
    Masuyama, Jun-ichi
    Sohma, Yoshiaki
    Inazawa, Hiroko
    Horie, Kaori
    Kojima, Kumiko
    Uemura, Yasunori
    Aoki, Yumi
    Kaga, Shuji
    Minota, Seiji
    Tanaka, Toshiyuki
    Yamaguchi, Yasunori
    Kobayashi, Tetsuto
    Serizawa, Isao
    CLINICAL IMMUNOLOGY, 2006, 120 (03) : 247 - 259
  • [4] The role of CD39-expressing regulatory T cells following treatment with αCD52: an effective therapeutic against central nervous system autoimmunity
    Brass, Sara Colpitts
    Burgess, Joseph N.
    Begum-Haque, Sakhina
    Kasper, Lloyd H.
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [5] CD52 as both a marker and an effector molecule of T cells with regulatory action: Identification of novel regulatory T cells
    Samten, Buka
    CELLULAR & MOLECULAR IMMUNOLOGY, 2013, 10 (06) : 456 - 458
  • [6] CD52 as both a marker and an effector molecule of T cells with regulatory action: Identification of novel regulatory T cells
    Buka Samten
    Cellular & Molecular Immunology, 2013, 10 : 456 - 458
  • [7] A pilot trial of Campath-1H and dose-adjusted EPOCH in CD52-expressing aggressive T-cell malignancies.
    Janik, JE
    Dunleavy, K
    Pittaluga, S
    Jaffe, ES
    Grant, N
    Shovlin, M
    Stetler-Stevenson, M
    Wilson, WH
    BLOOD, 2005, 106 (11) : 936A - 936A
  • [8] A pilot trial of alemtuzumab (campath-1H) and dose-adjusted EPOCH (DA- EPOCH) in CD52-expressing aggressive T cell malignancies
    Janik, John E.
    Dunleavy, Kieron E.
    Pittaluga, Stefania E.
    Jaffe, Elaine S.
    Grant, Nicole
    Shovlin, Margaret
    Sharma, Kamal
    Warfe, Gillian
    Stetler-Stevenson, Maryalice
    Wilson, Wyndham H.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2007, 23 (04) : 606 - 606
  • [9] In vivo control of diabetogenic T-cells by regulatory CD4+CD25+ T-cells expressing Foxp3
    Lundsgaard, D
    Holm, TL
    Hornum, L
    Markholst, H
    DIABETES, 2005, 54 (04) : 1040 - 1047
  • [10] A comparative study between T regulatory type 1 and CD4+CD25+ T cells in the control of inflammation
    Foussat, A
    Cottrez, F
    Brun, V
    Fournier, N
    Breittmayer, JP
    Groux, H
    JOURNAL OF IMMUNOLOGY, 2003, 171 (10): : 5018 - 5026
12345